Pet amiloide en la esclerosis múltiple

  1. Pytel, Vanesa
Dirigida per:
  1. Jorge Matías-Guiu Guía Director/a
  2. Jordi A. Matías-Guiu Director/a
  3. María Nieves Cabrera Martín Director/a

Universitat de defensa: Universidad Complutense de Madrid

Fecha de defensa: 30 de de setembre de 2019

Tribunal:
  1. José Luis Carreras Delgado President/a
  2. Francisco Grandas Pérez Secretari/ària
  3. Alfredo Rodríguez-Antigüedad Zarranz Vocal
  4. Mª Rosario Blasco Quílez Vocal
  5. Julián Benito León Vocal

Tipus: Tesi

Teseo: 150555 DIALNET lock_openDocta Complutense editor

Resum

Multiple sclerosis (MS) is the most common demyelinating disease and the main cause of non-traumatic neurological disability in young adults. It is a clinically heterogeneous disease, including motor, cognitive and fatigue symptoms. This is the result of a combination of the main pathophysiological processes involved: inflammation, demyelination, axonal damage and neurodegeneration. In recent years, various disease-modifying therapies have been developed, aimed at acting on the immune system, with an anti-inflammatory effect that prevents relapses and slows the progression of disability...